Waldenströms Macroglobulinemia

Waldenströms Macroglobulinemia
2024-02-13T00:00:00.000+11:00
Ongoing

Beigene BGB-11417-203

Beigene BGB-11417-203
Waldenström’s Macroglobulinemia

An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Patients With Relapsed/Refractory Waldenström’s Macroglobulinemia

An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Patients With Relapsed/Refractory Waldenström’s Macroglobulinemia

Trial overview

Clinical Area

Haematology

Disease / Condition

Waldenström’s Macroglobulinemia

Phase

II

Trial registration

Number: NCT05952037

Further information

Please click here for more information

GenesisCare Location(s)
North Shore
location pin icon

North Shore Health Hub, Tower A, Level 1, 7 Westbourne St, St Leonards, NSW, 2065, Australia

phone icon (02) 8037 4100 email icon admin.northshore@genesiscare.com
NSW
North Shore
Principal Investigator(s)
Haematologist

Dr David Kliman

MBBS (Hons), FRACP, FRCPA

Dr David Kliman
location pin icon

North Shore

View Profile
Profile Image - Dr David Kliman

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.